Evidence map›Paper›PMID 41600836›Full record

ArticleViruses2026

Novel 2-Aryl-1H-Benzimidazole Derivatives and Their Aza-Analogues as Promising Anti-Poxvirus Agents.

Valeria Manca, Laura Locci, Roberta Ibba, Laura Sanna, Ilenia Lupinu, Sandra Piras, Gabriele Murineddu, Gabriele Serreli, Roberta Loddo, Rebecca Piras and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Valeria MancaDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.
Laura LocciDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.
Roberta IbbaDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0003-3332-3845
Laura SannaDepartment of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0009-0000-9719-3512
Ilenia LupinuDepartment of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-9457-7737
Sandra PirasDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Gabriele MurinedduDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-2791-9178
Gabriele SerreliDepartment of Biomedical Science, Section of General Pathology, University of Cagliari, 09042 Monserrato, Italy.ORCID 0000-0002-1971-3989
Roberta LoddoDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.
Rebecca PirasDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.
Luca VirdisDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.ORCID 0009-0008-2124-6217
Michela IsolaDepartment of Biomedical Science, Section of Human Anatomy, University of Cagliari, 09042 Monserrato, Italy.
Vanessa PalmasDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.
Giuseppina SannaDepartment of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, 09042 Monserrato, Italy.ORCID 0000-0002-3999-4263
Antonio CartaDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Funding

NextGeneration EUMUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) Project no. PE00000007
6 · The paper itself

Abstract

introductionDespite the impressive progress carried out in the field of biomedical sciences in recent decades, the incidence of emerging and neglected lethal viral infections mainly belonging to the

methodsA combination of cell-based assays and experimental techniques was used to investigate the cytotoxicity, antiviral activity, and mechanisms of action of the most interesting compound.

resultsIn our study, new, variously substituted benzimidazoles showed interesting EC

conclusionsOur work shows that the new tested benzimidazole derivatives possess appealing activity and selectivity, accompanied by low cytotoxicity. These results set a valid foundation with which to identify potent and selective anti-Poxvirus agents.

Indexed as

Antiviral AgentsAza CompoundsBenzimidazolesOrthopoxvirusVaccinia virusAnimalsCell LineChlorocebus aethiopsHumansMonkeypox virusAntiviral AgentsAza CompoundsBenzimidazolesadsorption assayantiviral activitybenzimidazolesMPXVOrthopoxvirusTEERVV

Identifiers

PMID41600836
PMCPMC12846358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.